Company intelligence / Profile preview

Larena SAS

Ownership: Private
Development stage: Preclinical

Overview

Larena SAS primarily markets medicinal products and dietary supplements, especially the Symbiosys range based on probiotic strains. The company is involved in ex-vivo research evaluating the effects of probiotics and various drug classes on human intestinal microbiota. Clinical trial activity includes studies on how their products affect gut microbial communities[1].

Therapeutic areas: Gastroenterology
Modalities: Probiotics (dietary supplements)
Industry: Food & Nutrition

Drug pipeline

1 asset

melatonin

Pre-clinical

Indications: Sleep disorders, Inflammation, Oxidative stress, Liver disease, Neurodegeneration

Beyond the preview

Go deeper on Larena SAS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Larena SAS.

Explore the full profile